Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles (Q38068618)

28 August 2017

1 reference

title

Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles (English)

1 reference

28 August 2017

Taymaa May

1

1 reference

28 August 2017

Melina Shoni

2

1 reference

28 August 2017

Christopher P Crum

3

1 reference

28 August 2017

Wa Xian

4

1 reference

28 August 2017

Vinod Vathipadiekal

5

1 reference

28 August 2017

Michael Birrer

6

1 reference

28 August 2017

Barry Rosen

7

1 reference

28 August 2017

Alicia Tone

8

1 reference

28 August 2017

K Joan Murphy

9

1 reference

28 August 2017

language of work or name

English

0 references

publication date

16 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

128

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

488-492

1 reference

28 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Early events in the pathogenesis of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

The biology of ovarian cancer: new opportunities for translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Histopathologic grading of ovarian carcinoma: a review and proposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Diverse tumorigenic pathways in ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Tubal ligation and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

7 January 2021

Carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Utilization of a uniform grading system for interpreting serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Low-grade serous ovarian cancer: a unique disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Micropapillary serous ovarian carcinoma: surgical management and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Adjusting batch effects in microarray expression data using empirical Bayes methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

KLF4, p21 and context-dependent opposing forces in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Cyclosporine up-regulates Krüppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Ovarian cancer: strategies for overcoming resistance to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

A new histologic grading index in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2012.12.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2012.12.009

1 reference

28 August 2017

1 reference